News

FDA Panel Votes on Six Peptides: Could Retatrutide’s Regulatory Path Be Affected?
FDA advisory panel votes on six peptides, including retatrutide and AOD-9604, signaling tighter compounding rules. The split decision on AOD-9604 and Read more...
Retatrutide Compounding Risks Amid FDA GLP-1 Quality Concerns
FDA warning letters on retatrutide compounding highlight sterility failures and misbranding. Learn what the crackdown means for research peptide users Read more...
Retatrutide Compounding Crackdown: FDA Warning Letters Signal Shift After GLP-1 Quality Concerns
FDA warning letters to compounding pharmacies signal a crackdown on retatrutide and AOD-9604 after GLP-1 quality failures. The enforcement shift Read more...
Retatrutide Compounding Under Fire After GLP-1 Quality Study
A MedPage Today investigation into compounded GLP-1 quality raises safety flags for retatrutide users. Learn what the findings mean for pharmacy Read more...
Retatrutide Trial Data: Regulatory Implications for Compounding Pharmacies
Retatrutide's Phase 2 trial data showing 24% weight loss raises urgent regulatory questions for compounding pharmacies. This analysis examines FDA Read more...